Game On: Court Ruling on Myriad Patents to Kick off Protracted Legal Battle Over DNA Patentability

A US District Court's ruling that Myriad's BRCA patents are invalid will definitely be appealed in the Federal Circuit, and will probably reach the Supreme Court, according to legal experts.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.